2022年1月6日至2022年3月21日中国香港特别行政区的新冠病毒病死亡率及疫苗接种率
COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
作者信息
Smith Dallas J, Hakim Avi J, Leung Gabriel M, Xu Wenbo, Schluter W William, Novak Ryan T, Marston Barbara, Hersh Bradley S
机构信息
CDC COVID-19 Response International Task Force, Atlanta.
Epidemic Intelligence Service, CDC.
出版信息
China CDC Wkly. 2022 Apr 8;4(14):288-292. doi: 10.46234/ccdcw2022.071.
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: COVID-19 vaccines are important tools to protect populations from severe disease and death.
WHAT IS ADDED BY THIS REPORT?: Among persons aged ≥60 years in Hong Kong, 49%, had received ≥2 doses of a COVID-19 vaccine, and vaccination coverage declined with age. During January-March 2022, reported COVID-19-associated deaths rose rapidly in Hong Kong. Among these deaths, 96% occurred in persons aged ≥60 years; within this age group, the risk for death was 20 times lower among those who were fully vaccinated compared with those who were unvaccinated.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Efforts to identify and address gaps in age-specific vaccination coverage can help prevent high mortality from COVID-19, especially in older adults.
摘要
关于该主题已知的信息有哪些？：新冠疫苗是保护人群免受重症和死亡的重要工具。
本报告新增了哪些内容？：在香港60岁及以上人群中，49%的人接种了≥2剂新冠疫苗，且疫苗接种覆盖率随年龄增长而下降。在2022年1月至3月期间，香港报告的新冠相关死亡人数迅速上升。在这些死亡病例中，96%发生在60岁及以上人群中；在该年龄组内，与未接种疫苗的人相比，完全接种疫苗的人死亡风险低20倍。
对公共卫生实践有何启示？：识别和解决特定年龄组疫苗接种覆盖率差距的努力有助于预防新冠导致的高死亡率，尤其是在老年人中。
相似文献
1
COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.2022年1月6日至2022年3月21日中国香港特别行政区的新冠病毒病死亡率及疫苗接种率
China CDC Wkly. 2022 Apr 8;4(14):288-292. doi: 10.46234/ccdcw2022.071.
2
COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.2022 年 1 月 6 日至 2022 年 3 月 21 日，中国香港特别行政区的 COVID-19 死亡率和疫苗接种率。
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):545-548. doi: 10.15585/mmwr.mm7115e1.
3
Association Between COVID-19 Vaccination Coverage and Case Fatality Ratio: a Comparative Study - Hong Kong SAR, China and Singapore, December 2021-March 2022.2021年12月至2022年3月中国香港特别行政区与新加坡新冠疫苗接种覆盖率与病死率之间的关联：一项比较研究
China CDC Wkly. 2022 Jul 29;4(30):649-654. doi: 10.46234/ccdcw2022.140.
4
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性：一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
5
Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis.疫苗对香港应对2019冠状病毒病大流行的经济价值：一项成本效益分析。
Vaccines (Basel). 2022 Mar 23;10(4):495. doi: 10.3390/vaccines10040495.
6
COVID-19 outbreaks in residential care homes in Hong Kong and effectiveness of vaccine against severe outcomes.香港安老院舍的2019冠状病毒病疫情及疫苗预防严重后果的有效性
Infect Med (Beijing). 2023 Mar;2(1):1-10. doi: 10.1016/j.imj.2023.01.002. Epub 2023 Jan 14.
7
Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series.在香港，60 岁及以上人群中使用灭活全病毒 COVID-19 疫苗（科兴疫苗）的安全性：一项修改后的自身对照病例系列研究。
Lancet Healthy Longev. 2022 Jul;3(7):e491-e500. doi: 10.1016/S2666-7568(22)00125-8. Epub 2022 Jul 4.
8
Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.BNT162b2疫苗和科兴疫苗在香港奥密克戎毒株占主导期间对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）传播的有效性：一项关于2019冠状病毒病病例的回顾性队列研究
J Clin Virol. 2023 Sep;166:105547. doi: 10.1016/j.jcv.2023.105547. Epub 2023 Jul 10.
9
Public health impact of herpes zoster vaccination on older adults in Hong Kong.香港老年人接种带状疱疹疫苗的公共卫生影响。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2176065. doi: 10.1080/21645515.2023.2176065. Epub 2023 Feb 28.
10
Multilevel Determinants of COVID-19 Vaccine Uptake Among South Asian Ethnic Minorities in Hong Kong: Cross-sectional Web-Based Survey.香港南亚少数族裔对 COVID-19 疫苗接种的多层次决定因素：基于网络的横断面调查。
JMIR Public Health Surveill. 2021 Nov 9;7(11):e31707. doi: 10.2196/31707.
引用本文的文献
1
Explanatory spatial modeling of COVID-19 vaccine coverage in Thailand: policy implications for equitable distribution.泰国新冠疫苗接种覆盖率的解释性空间建模：公平分配的政策影响
BMC Public Health. 2025 Sep 2;25(1):3028. doi: 10.1186/s12889-025-24217-7.
2
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Hospitalized Older Adults with Severe Omicron COVID-19: A Retrospective Cohort Study from China.奈玛特韦/利托那韦对住院的重症奥密克戎新冠病毒肺炎老年患者的真实世界疗效：一项来自中国的回顾性队列研究
Infect Drug Resist. 2025 Jun 7;18:2901-2909. doi: 10.2147/IDR.S518205. eCollection 2025.
3
Risk of extended viral shedding of Omicron BA.2 in Shanghai: Implications for vaccination strategy optimization.上海奥密克戎BA.2毒株病毒长期脱落的风险：对优化疫苗接种策略的启示
Chin Med J Pulm Crit Care Med. 2023 Dec 7;1(4):241-248. doi: 10.1016/j.pccm.2023.11.001. eCollection 2023 Dec.
4
Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.奈玛特韦-利托那韦与莫努匹拉韦治疗晚期肾病患者新冠病毒感染的安全性和疗效比较：一项回顾性观察研究
EClinicalMedicine. 2024 May 3;72:102620. doi: 10.1016/j.eclinm.2024.102620. eCollection 2024 Jun.
5
Young adults' intention to encourage COVID-19 vaccination among their grandparents: A nationwide cross-sectional survey of college students in China.年轻人鼓励祖父母接种新冠疫苗的意愿：一项针对中国大学生的全国性横断面调查。
Vaccine X. 2024 Jan 17;16:100439. doi: 10.1016/j.jvacx.2024.100439. eCollection 2024 Jan.
6
Vaccine Effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 in CKD.BNT162b2 和 CoronaVac 疫苗对慢性肾脏病患者中 SARS-CoV-2 奥密克戎 BA.2 的有效性。
Clin J Am Soc Nephrol. 2024 Apr 1;19(4):418-428. doi: 10.2215/CJN.0000000000000376. Epub 2023 Dec 26.
7
COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020-2021.2020-2021 年 45 个高收入国家德尔塔变异株流行期间的 COVID-19 流行病学
Emerg Infect Dis. 2023 Sep;29(9):1757-1764. doi: 10.3201/eid2909.230142. Epub 2023 Jul 26.
8
An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.鼻腔内接种流感病毒载体疫苗可预防 SARS-CoV-2 在小鼠和仓鼠呼吸道组织中的复制。
Nat Commun. 2023 Apr 12;14(1):2081. doi: 10.1038/s41467-023-37697-1.
9
Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2.与感染奥密克戎 BA.2.2 的老年患者病毒持续排出相关的因素。
Front Public Health. 2023 Jan 12;10:1087800. doi: 10.3389/fpubh.2022.1087800. eCollection 2022.
10
Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.尼马瑞韦-利托那韦治疗和 COVID-19 疫苗接种改善了 SARS-CoV-2 奥密克戎变异株感染的临床结局。
J Med Virol. 2023 Feb;95(2):e28497. doi: 10.1002/jmv.28497.
本文引用的文献
1
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.BNT162b2 和科兴疫苗一剂、两剂和三剂对香港 COVID-19 的疫苗有效性：基于人群的观察性研究。
Lancet Infect Dis. 2022 Oct;22(10):1435-1443. doi: 10.1016/S1473-3099(22)00345-0. Epub 2022 Jul 15.
2
Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China.中国老年人和慢性病患者对 COVID-19 疫苗的接种意愿。
Hum Vaccin Immunother. 2021 Dec 2;17(12):4873-4888. doi: 10.1080/21645515.2021.2009290. Epub 2021 Dec 14.
3
Interpretation of the Protocol for Prevention and Control of COVID-19 in China (Edition 8).《新型冠状病毒肺炎防控方案（第八版）》解读
China CDC Wkly. 2021 Jun 18;3(25):527-530. doi: 10.46234/ccdcw2021.138.
4
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.从中国武汉的传播动态估计 COVID-19 的临床严重程度。
Nat Med. 2020 Apr;26(4):506-510. doi: 10.1038/s41591-020-0822-7. Epub 2020 Mar 19.
Zotero 插件